Reactivation of Toxoplasma gondii Infection in Patients under Biological Treatment by Antitumor Necrosis Factor Alpha (anti-TNFα)
Khadiga Ahmed Ismail*
Medical Laboratory Department, Faculty of Applied Medical Science, Taif University, Taif, Saudi Arabia.
Department of Parasitology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
Toxoplasma gondii (T. gondii) is considered as a one of the highly resistant intracellular parasite mainly found in the central nervous system (CNS), however, it can persist in multiple tissues in the body. Moreover, T. gondii is causing infections among the patients under biological treatment for different autoimmune diseases. Thus, the aim of this study was to investigate the frequency of T. gondii infection among patients under biological treatment for different autoimmune diseases in Taif- Saudi Arabia. Fifty patients under biological treatment with anti-TNF-α for different autoimmune diseases and thirty healthy control were subjected to determination of anti T. gondii immunoglobulin M (IgM) antibody seropositivity and anti T. gondii immunoglobulin G (IgG) antibody seropositivity using commercially available enzyme-linked immuno sorbent assay kits (ELISA). The results showed that the seropositivity rate of anti T. gondii IgM antibodies and anti T. gondii IgG antibodies was found as 24% and 40% respectively and it indicates results are statistically significant. These statistically significant results support the association between T. gondii infection and the use of anti-TNF-α and suggest the usefulness of performing serological test for detection of previous infection by toxoplasma to avoid reactivation of the latent infection during treatment with anti-TNF-α.
Key words: Toxoplasma gondii, Anti-TNF-α, Systemic lupus erythematosus, Psoriasis, Chron’s disease.